KRAS and diffuse large B-cell lymphoma: The prevalence of DLBCL with positive CD30 expression at the >0% cut-off was 24.2% and at the >20% cut-off was 7.2%; the prevalence of DLBCL with positive HCV NS3 expression was 24.2%, according to our findings.